AGP Executive Report
Last update: 8 hours agoDrug Development: Freiburg-based Dr. Falk Pharma and Ireland’s Renexxion say US and European regulators have agreed on Phase 3 trials of naronapride for gastroparesis, planned to start in early 2027. Hospital Digitalization: The EU approved Germany’s final €6 billion Covid recovery payment, bringing its total to €30.3 billion; funding supported digital systems at more than 1,600 hospitals. Outbreak Response: Three passengers from a suspected norovirus-hit Eurowings flight from Rhodes were taken to hospital after an emergency landing in Düsseldorf. German Medical Technology: An Israeli patient became the first outside Europe to receive a non-invasive epilepsy treatment developed in Germany, which stimulates the brain through the skull. Cell Research: Bonn researchers reported resetting aging markers in reprogrammed cells from an 80-year-old donor, a laboratory finding rather than an anti-aging treatment.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
